Liver-Microbiome Axis in Health and Disease
- PMID: 29843959
- DOI: 10.1016/j.it.2018.05.002
Liver-Microbiome Axis in Health and Disease
Abstract
The intestinal and hepatobiliary tract exhibits host-specific commensal colonization. The resident microbiota has emerged as a key player in intestinal and hepatic diseases. Alcoholic and nonalcoholic fatty liver diseases (ALD/NAFLD), primary sclerosing cholangitis (PSC), liver cirrhosis, and some of their clinical complications, such as hepatic encephalopathy (HE), have been linked to a microbial signature, as also observed for severe liver inflammation in alcoholic hepatitis. In turn, the liver impacts, and communicates with, the microbiota through hepatic mediators, such as bile acids or inflammatory signals. Therefore, a liver-microbiome bidirectional crosstalk appears to be critical in health and various liver diseases and could be therapeutically targeted, such as by fecal microbiota transplantation.
Keywords: alcoholic liver disease; bile acids; hepatic encephalopathy; intestinal microbiota; liver cirrhosis; metabolism; non-alcoholic fatty liver disease; primary sclerosing cholangitis.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Similar articles
-
Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice.J Hepatol. 2017 Apr;66(4):806-815. doi: 10.1016/j.jhep.2016.11.008. Epub 2016 Nov 25. J Hepatol. 2017. PMID: 27890791
-
Gut-liver axis: Pathophysiological concepts and clinical implications.Cell Metab. 2022 Nov 1;34(11):1700-1718. doi: 10.1016/j.cmet.2022.09.017. Epub 2022 Oct 7. Cell Metab. 2022. PMID: 36208625 Review.
-
Gut microbiome and liver diseases.Gut. 2016 Dec;65(12):2035-2044. doi: 10.1136/gutjnl-2016-312729. Epub 2016 Oct 8. Gut. 2016. PMID: 27802157 Review.
-
Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases.Autoimmun Rev. 2017 Sep;16(9):885-896. doi: 10.1016/j.autrev.2017.07.002. Epub 2017 Jul 8. Autoimmun Rev. 2017. PMID: 28698093 Review.
-
Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature.Int J Mol Sci. 2019 Jan 17;20(2):395. doi: 10.3390/ijms20020395. Int J Mol Sci. 2019. PMID: 30658519 Free PMC article. Review.
Cited by
-
Early prediction of incident liver disease using conventional risk factors and gut-microbiome-augmented gradient boosting.Cell Metab. 2022 May 3;34(5):719-730.e4. doi: 10.1016/j.cmet.2022.03.002. Epub 2022 Mar 29. Cell Metab. 2022. PMID: 35354069 Free PMC article.
-
Current Knowledge about the Effect of Nutritional Status, Supplemented Nutrition Diet, and Gut Microbiota on Hepatic Ischemia-Reperfusion and Regeneration in Liver Surgery.Nutrients. 2020 Jan 21;12(2):284. doi: 10.3390/nu12020284. Nutrients. 2020. PMID: 31973190 Free PMC article. Review.
-
Recent Advances of Microbiome-Associated Metabolomics Profiling in Liver Disease: Principles, Mechanisms, and Applications.Int J Mol Sci. 2021 Jan 25;22(3):1160. doi: 10.3390/ijms22031160. Int J Mol Sci. 2021. PMID: 33503844 Free PMC article. Review.
-
Epigallocatechin Gallate Protects Mice against Methionine-Choline-Deficient-Diet-Induced Nonalcoholic Steatohepatitis by Improving Gut Microbiota To Attenuate Hepatic Injury and Regulate Metabolism.ACS Omega. 2020 Aug 12;5(33):20800-20809. doi: 10.1021/acsomega.0c01689. eCollection 2020 Aug 25. ACS Omega. 2020. PMID: 32875214 Free PMC article.
-
Gut Microbiota and Liver Regeneration: A Synthesis of Evidence on Structural Changes and Physiological Mechanisms.J Clin Exp Hepatol. 2024 Nov-Dec;14(6):101455. doi: 10.1016/j.jceh.2024.101455. Epub 2024 Jun 8. J Clin Exp Hepatol. 2024. PMID: 39035190 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources